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Abstract
Background—Sample processing for real-time reverse transcriptase polymerase chain reaction 
(rRT-PCR) based diagnostic assays requires stabilizing sample ribonucleic acid (RNA) in lysis 
buffer prior to testing. The stability of viral RNA prior to processing is difficult to assure. It is 
unknown if clinical sample integrity is compromised by delays in processing, as may occur due to 
weekends and holidays. We sought to examine the integrity of respiratory specimens with variable 
processing times.
Study Design—Upper respiratory specimens were collected during 3 influenza seasons 
2009-2012 and tested for influenza virus and internal control human RNase P (RNP) RNA by rRT-
PCR. Time to processing was measured in hours from specimen collection to placement in lysis 
buffer.
Results—635 (11.4%) of 5583 samples were influenza positive. Mean and median times to 
processing were 11.5 hours and 6.0 hours respectively (min 0.1h, max 105.2h). There were no 
significant associations between time to processing and presence of RNP (OR=1.0, p=0.740), or 
detection of influenza (OR=1.0, p=0.060). Longer duration of illness was associated with a lower 
likelihood of influenza detection (OR=0.92, p<0.001) and with increased influenza A cycle 
threshold (Ct) values (p<0.001), while older age was associated with increased influenza B Ct 
values (p=0.001), indicating the presence of less amplifiable RNA.
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Conclusion—Delays in time to processing of upper respiratory specimens up to 105 hours were 
not associated with decreased detection of amplifiable RNA, suggesting specimen integrity is not 
compromised by such delays.
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Background
Real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) has become the gold 
standard for the detection of respiratory viruses. With this method of detection, specimen 
processing requires nucleic acid stability rather than organism viability previously needed 
for culture. Many studies have compared various types of specimens, swabs, and processing 
buffers for influenza and other respiratory virus RT-PCR assays [1–4]. Laboratory-based 
studies have found that influenza RNA was stable on dry swabs for days prior to processing 
if kept at room temperature or cooler [5, 6]. However, another study found that delayed 
processing of respiratory specimens resulted in lower influenza detection by molecular 
testing [7]. Our study evaluated the presence and amount of both influenza and human RNA 
in clinical samples with variable processing times using rRT-PCR.
It is common for laboratories to suspend testing over weekends and holidays due to 
technician staffing. Additionally, such laboratories typically batch influenza testing during 
studies. We sought to examine the integrity of respiratory specimens with variable 
processing times for the testing of influenza. A secondary objective was to evaluate the 
association between presence and amount of amplifiable RNA and processing time, 
adjusting for age and duration of illness.
Study Design
Study Population
5633 patients with acute respiratory illness presenting for medical care were enrolled from 
various inpatient and outpatient clinical settings in the Nashville area during three influenza 
seasons 2009-2012. Demographic and clinical information were collected using 
questionnaires and case report forms [8]. Duration of illness was defined as total days from 
onset of symptoms until date of specimen collection.
Clinical Samples and Laboratory Testing
Both nasal and throat swabs were collected from each study participant and placed into the 
same vial of viral transport medium at time of collection. Samples were kept on ice until 
they arrived at the laboratory where they were placed into a 4°C refrigerator until processed. 
Processing included placing an aliquot into lysis buffer prior to RNA extraction, and 
followed by testing for influenza A, influenza B, and RNAse P (RNP) RNA using real time 
RT-PCR [9]. Time to processing was defined as time in minutes from collection of specimen 
until the specimen was placed in lysis buffer. Samples were processed on weekdays only, 
leading to delayed processing for weekend and holiday samples.
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Statistical Analysis
Descriptive analyses were conducted. Two-sample T-tests were used to compare the mean 
cycle threshold (Ct) values between early and late processed specimens. Multivariable 
logistic and linear regression models were used to evaluate the association between presence 
and amount of amplifiable RNA respectively with processing time adjusting for age at time 
of illness, and duration of illness. Variables included in both the multivariable logistic and 
linear regression models were time to processing, age at time of illness, and duration of 
symptoms prior to specimen collection. Ct values were used as a semi-quantifiable surrogate 
for amount of RNA present which was the outcome variable in the multivariable linear 
regression model. All analyses were performed using Stata 12.1.
Results
There were 5583 of 5633 (99.1%) enrollees who had amplifiable human RNA indicating the 
majority of samples were adequate in regards to sample collection and successful nucleic 
acid extraction. All 5633 samples were included in further analysis to evaluate for an 
association between the presence of amplifiable RNA and processing time using the multiple 
logistic regression model. The 50 samples that failed to amplify internal control RNA were 
excluded in the multiple linear regression model. Mean and median sample time to 
processing was 11.5 hours and 6.0 hours, respectively, with a range of 0.1 to 105.2 hours. 
Study demographics and clinical information are shown in Table 1. Specimens with negative 
RNP test results were not significantly different from the specimens that amplified internal 
control RNA when comparing mean (12.5h vs 11.5h; p=0.267) or median (6h vs 6.3h; 
p=0.444) time to processing, mean (32.4y vs 32.6y; p=0.518) or median (36.5y vs 29.2y; 
p=0.448) age of patient, and mean (3.7d vs 4.1d; p=0.151) or median (3d vs 3d) duration of 
illness respectively (data not shown). Of the 5583 internal control positive samples, 635 
(11.4%) were influenza positive; 469 (8.4%) influenza A, 163 (2.9%) influenza B, and 3 
(0.1%) influenza A and B co-infections. 
Mean Ct values were similar for influenza A, influenza B, and human RNP assays and there 
were no statistical significant difference between samples processed ≤ 24 hours and >24 
hours (Table 2).
Specimens with increased time to processing trended towards negative influenza test results 
though this was not statistically significant. There was no association between increased 
time to processing and the presence of either influenza (p=0.062; OR=1.0) or human 
(p=0.740; OR=1.0) RNA using multivariable logistic regression models (Figure 1 A–B). 
Older age (p<0.001; OR=0.99) and longer duration of illness (p<0.001; OR=0.92) were both 
associated with a lower likelihood of influenza detection (Figure 1C and 1E).
The amount of amplifiable influenza A (p=0.651; 95% CI=−0.03, 0.05), influenza B 
(p=0.133; 95% CI=−0.02, 0.15), and human RNP (p=0.797; 95% CI=−0.01, 0.01) RNA was 
not impacted by increased processing time (Figure 2A). Older age was associated with less 
amplifiable influenza B (p=0.001; 95% CI=0.02, 0.09) and human RNP (p<0.001; 95% 
CI=0.02, 0.03) RNA (Figure 2B). There was less amplifiable influenza A RNA with older 
age though it was not statistically significant (p=0.187; 95% CI=−0.01, 0.04). Prolonged 
Dare et al. Page 3
J Med Virol. Author manuscript; available in PMC 2018 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
duration of illness was associated with less amplifiable influenza A (p<0.001; 95% CI=0.23, 
0.65) and human RNP (p<0.001; 95% CI=0.06, 0.11) RNA (Figure 2C). There was less 
amplifiable influenza B RNA with prolonged duration of illness though it was not 
statistically significant (p=0.606; 95% CI=−0.34, 0.58).
Discussion
In this study, increased time to processing up to 4 days, when samples were maintained at 
4°C, did not affect the presence and amount of influenza and human RNA. There was a non-
significant trend towards less amplifiable influenza B RNA with increased time to 
processing. It is unclear if this trend is insignificant due to low number of influenza B 
positive samples in this study or if there is truly no clinical significance.
Older patients were more likely to have negative influenza test results than younger patients. 
Interestingly, older patients had less amplifiable influenza B and RNP RNA with a non-
significant trend towards less amplifiable influenza A RNA. The cause(s) of this is unknown, 
though higher annual influenza vaccine rates could explain the decrease in infection rate and 
possibly decreased shedding. Decreased human and viral shedding with increased age could 
also be explained by drier mucous membranes secondary to age and supplemental oxygen 
usage.
Patients presenting further into the course of illness were more likely to have a negative 
influenza test result. These patients also had less amplifiable influenza A RNA and, though 
not significant, a trend towards less amplifiable influenza B RNA highlighting early viral 
RNA shedding early in the course of illness.
Older patients and those with a prolonged course of illness were less likely to have influenza 
RNA detected, pointing out the limits of these assays for this population. When testing these 
patients, providers should interpret negative results with caution. Additionally, this 
highlights the need for appropriate sample collection. Weather obtaining specimens from 
various sites to enhance the yield of detection in this susceptible patient population is 
unknown. Older adults may present with late complications of influenza at a time when 
virus is no longer detectable.
Additionally, there was more amplifiable human RNP RNA early in the course of influenza 
illness, suggesting increased epithelial shedding with active viral infection. Other 
possibilities include decreased epithelial shedding late in infection due to an unhealthy 
epithelium. Interventions routinely used during influenza infections such as supplemental 
oxygen, steroid nasal sprays, alpha agonist nasal sprays, and other over the counter remedies 
can alter the character of the nasal and oropharyngeal epithelium, affecting available 
amplifiable RNA.
There are limitations to this study, as it was a retrospective analysis using samples from an 
influenza surveillance study [8]. Mean and median time to processing was 11.5 hours and 
6.0 hours respectively ranging from 0.1 to 105.2 hours with a majority (84%) of samples 
processed within 24 hours. Though there was not a significant impact on the presence or 
amount of amplifiable influenza RNA, our study only included samples with processing time 
Dare et al. Page 4
J Med Virol. Author manuscript; available in PMC 2018 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
up to 4 days. It remains unclear if samples processed after 4 days would be affected by such 
a delay, and if so, at what time would sample integrity be affected. Caselton et al. showed 
similar results when processing was performed up to 5 days; however, they noted a 
decreased rate of influenza detection when samples were processed 6 days or later [7]. In 
our study, there were only 163 influenza B positive samples, limiting inferences from these 
analyses. This study only assessed patients with influenza infection; thus, it remains unclear 
if detection of nucleic acid from other respiratory viruses would be impacted by similar 
processing delays. In addition, it is unclear whether these results apply to other populations 
such as infants, children, and adults in other clinical settings, including patients with 
respiratory symptoms up to 30 days.
Delaying diagnostic assays in patient care settings is not advocated, especially when 
treatment could be altered; however, many research laboratories are not routinely staffed 
during weekends and holidays. These data give reassurance that influenza RNA is stable on 
refrigerated clinical swabs up to 4 days.
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Figure 1. 
Boxplot of min, max, median and interquartile range of (A) time to processing (hours), (C) 
age (years), and (E) duration of illness (days) for influenza negative and positive specimens. 
Boxplot of min, max, median and interquartile range of (B) time to processing (hours), (D) 
age (years), and (F) duration of illness (days) for human RNase P (RNP) negative and 
positive specimens. Influenza RNA includes both influenza A and B.
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Figure 2. 
(A) Impact of time to processing (hours), (B) age (years), and (C) duration of illness (days) 
on the amount of influenza A, influenza B, and human RNAse P (RNP) RNA.
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Table 1
Demographic and Clinical Information.
Specimens (5633) RNP+ 5583 (99.1)
 Influenza + (RNP+)  635 (11.4)
 Influenza A+ (RNP+)  469 (8.4)
 Influenza B+ (RNP+)  163 (2.9)
 Influenza A and B+ (RNP+)  3 (0.3)
Season 2009-2010 3688 (65.5)
2010-2011 1624 (29.1)
2011-2012 321 (5.7)
Location Inpatient 2321 (41.2)
Outpatient 1725 (30.6)
ED 1587 (28.2)
Sex Male 3043 (54.0)
Female 2590 (46.0)
Age Range (Years) 0.01-102.4
Mean ± SD (Years) 32.6 ± 28.0
<18yr 2289 (40.6)
≥18yr 3344 (59.4)
Race White 3224 (57.2)
Black 1488 (26.4)
Hispanic 810 (14.4)
Asian 49 (0.9)
Other 62 (1.1)
Days III Range (Days) 0-30
Mean ± SD (Days) 3.7 ± 4.1
Time to Processing Range (Hrs) 0.1-105.2
Mean ± (Hrs) 11.5 ± 11.7
Median (IQR: 25%, 75%) (Hrs) 6.0 (4.2, 20.5)
ED, Emergency Department; Hrs, hours; SD, Standard Deviation; IQR, Interquartile Range
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